Scotland's health regulator approves five new medications for NHS Scotland.

Scotland's health regulator, the Scottish Medicines Consortium (SMC), has approved five new medications for NHS Scotland, including Selinexor for multiple myeloma, Pembrolizumab for high-risk non-small cell lung cancer, and Relugolix for advanced hormone-sensitive prostate cancer. These treatments are deemed "game-changers" for patients, enhancing accessibility and safety across the UK. Additional approvals include Rezafungin for invasive candidiasis and Faricimab for vision impairment.

October 07, 2024
3 Articles